According to a new study of more than 119,000 hospitalizations, the costs associated with TAVR are far from consistent. 

Researchers explored data from nearly 25,000 PCI procedures, tracking the outcomes of patients treated with transradial access and transfemoral access. 

The annual list, now in its 17th year, was designed to celebrate companies that make ethical business practices a high priority. 

A team of specialists examined new outcomes data related to the SAPIEN 3 Ultra transcatheter heart valve, sharing its findings in EuroIntervention.

Identifying patients with severe aortic stenosis who could potentially benefit from transcatheter aortic valve replacement (TAVR) is very important—but managing and tracking them over time can be quite a challenge.

When the ACC and AHA collaborated on new valvular heart disease guidelines in 2020, the two groups highlighted the importance of interventional treatment options such as TAVR. However, an estimated one-third of patients with severe aortic stenosis in the U.S. still lack a guideline-recommended treatment plan.

Researchers examined data from more than 700 TAVR patients, publishing their findings in the American Journal of Cardiology.

SGLT2 inhibitors such as dapagliflozin and empagliflozin are associated with improved outcomes among many heart failure patients. The medications are not cost-effective, however, limiting their overall value. Read the full economic analysis to learn more.